Maysa Vilbert
@MaysaVilbertOncologist passionate about enhancing the lives of cancer survivors, advancing cancer research, and investigating immune toxicities.
Similar User
@AlineFaresMD
@ESaldanhaMD
@IanHirsch3
@7sevanh
@ChristineChili1
Here is our next episode- Thought leaders in #irAE @kreynoldsMD @lexameara @EladSharonMD and CPN hosts @afreenshariffmd @FunchainMD discuss the International Alliance- ASPirE (link in comments). Tune in to learn abt ASPirE and how you can join us! podcasts.apple.com/us/podcast/sea…
Just released! Our meta-analysis underscores the importance of increasing awareness about lorlatinib-related neurocognitive adverse events (NAEs) to improve their recognition and reporting, thereby enhancing NSCLC patients' quality of life. Link: mdpi.com/2072-6694/16/1…
Hot off the press! Our meta-analysis supports EGFR-TKI rechallenge as a valid strategy in metastatic #NSCLC. This may offer an alternative to overcoming treatment access barriers in low- and middle-income countries. mdpi.com/2870852 @JPM_MDPI
SCI member Pauline Funchain has joined the newly launched Immune-Related Adverse Events (irAE) Consortium, which aims to unite clinicians, researchers, and patients to advance clinical care and advocacy. bit.ly/4aRqc7w @ASCOPost @FunchainMD
Yes correct - if anyone from the #ASCO24 Security team asks, I just joined, yesterday in fact. I have no idea whose portable hand truck carried the pizzas in 🤷♀️ For everyone else with interest and unable to join us at ASPirE (formerly known as irAE consortium), DM me ☺️
SCI member Pauline Funchain has joined the newly launched Immune-Related Adverse Events (irAE) Consortium, which aims to unite clinicians, researchers, and patients to advance clinical care and advocacy. bit.ly/4aRqc7w @ASCOPost @FunchainMD
SU2C-SARC032 randomized trial comparing neoadj RT +/- pembrolizumab for high risk STS (UPS/LPS) demonstrated HR 0.57 for DFS favoring IO. Promising strategy for G3 pts. Great initiative, collaboration, and outstanding presentation by Dr. @DKirschMDPhD from @PMResearch_UHN @UofT
Please come and visit our poster n506 « Efficacy of Osimertinib in uncommon EGFR mutations” review and meta-analysis @jpriantti will there to charmingly answer all your questions. Honored to be a co-authors @JairBar4 @ACortelliniMD @thenasheffect #ASCO24
ASPirE gathered so many incredible clinicians, researchers and change makers at #ASCO24 - humbling and inspiring how much this group is devoted to improving immunotherapy outcomes 💪 #irAE
Excited to see our #MetaMasters and Experts shining at the ASCO 2024 conference in Chicago. Amazing work team! #ASCO2024 #MedTwitter #OncoDaily
Pooled analysis of TKI for advanced Ewing Sarcoma. Thanks for the wonderful support and mentorship @LudiCa19862 😃!
Presenting our data in Ewing sarcoma at #ASCO24 Elite work by @MaysaVilbert @jpriantti Meta-analysis evaluating second line TKIs in Ewing Sarcoma @metaacademy_ofc @UVA
Presenting our data in Ewing sarcoma at #ASCO24 Elite work by @MaysaVilbert @jpriantti Meta-analysis evaluating second line TKIs in Ewing Sarcoma @metaacademy_ofc @UVA
Congrats @karineskandar and @juoliveira_md ! @metaacademy_ofc
Thank you @juoliveira_md for inviting me to this collaboration. This is such an important topic and so much more to be added to its knowledge. First paper of the year 📝🤩
@ACCinTouch @ACCmediacenter @BorraVamsireddy @ZainAsadEP @DrBrijPatel @SarjuGanatraMD @oncocardiology @Card_Onco @CardioOncology @CardioOnco @anita_deswal @KimberlyKooi @CampbellMDPhD @buenaaziri @EKoutroumpakis @Wamique @PalaskasN @cezar_ciliescu
Day 2 of #irAE2024 management conference How many of these therapies do you know? 🤯 the interaction between ICI therapies, their toxicities, &therapies borrowed from autoimmune disorders is ever expanding. GI/Hep irAEs today at 10:50 AM 🔗ghlf.org/irae-consortiu…
& I thought the IBD pipeline is daunting! This is the expansion of immune checkpoint inhibitors across indications 🤩@kreynoldsMD kicking off the 5th annual management of ICI toxicity My year-in-review GI toxicities talk is tomorrow🌟 Join virtually ghlf.org/irae-consortiu…
Amazing night, amazing cause, amazing company, amazing venue - could not have asked for a better launch to fund a brand new irAE patient advocacy group 🙏✨ @EdwinsCLE @GHLForg @ProjDataSphere @kreynoldsMD @afreenshariffmd @lexmeara @EladSharonMD @LCalabreseDO @DrJustineCohen
The inaugural irAE class of 2024: the birth of a consortium closely married to a patient advocacy group. The passion for advancing patient outcomes was palpable! #irAE24
It’s a wrap for #irAE24 Tx to the @ClevelandClinic team @FunchainMD for hosting us and my co organizers @kreynoldsMD @lexmeara @EladSharonMD @mimiwang for being the best partners in this passion project. Looking forward to hosting the next #irAE25 thinktank at @DukeCancerNETWK
Good afternoon! 🌞 Beautiful day in the CLE to talk about irAE at the 5th annual Management of Checkpoint Inhibitor Related Toxicity @ClevelandClinic #CleClinicCancer
💥🚨Happy to share these two papers out today in the same issue of @JCOPO_ASCO 1) multi omics work on Stk11 NSCLC with @carisls and 2) biomaker prediction in #irAEs using machine learning and omics approaches (thread below). Lots of people to thank below @HMAbushukair @carisls
Excited to announce the publication of our paper on TIME features and #irAEs in @JCOPO_ASCO! Can't thank Dr. @thenasheffect enough for this opportunity and his mentorship Huge shout out to the all-star team, learned a lot from you guys! ascopubs.org/doi/pdf/10.120… Tweetorial below:
Our latest meta-analysis on the use of T-DXd among patients with breast cancer brain metastasis showed durable PFS and > 50% intracranial objective response rate! Out now on @ESMO_Open
In a meta-analysis of 10 studies by Michelin et al, published on @ESMO_Open, T-DXd was found associated with relevant intracranial activity among patients with breast cancer brain metastases (IC-ORR 61%, mPFS 15 months). Read the article here: esmoopen.com/article/S2059-…
United States Trends
- 1. soobin 100 B posts
- 2. Cowboys 72,5 B posts
- 3. KADOKAWA 39,4 B posts
- 4. #tuesdayvibe 2.833 posts
- 5. Fultz 1.740 posts
- 6. Clippers 12,3 B posts
- 7. #EeveeDay N/A
- 8. Eliza 13,9 B posts
- 9. Jerry 42,1 B posts
- 10. Norman Powell 2.162 posts
- 11. #پاکستان_میری_پہچان 1.089 posts
- 12. Eevee Evolution N/A
- 13. sabrina 115 B posts
- 14. FromSoftware 5.271 posts
- 15. The Herta 29,3 B posts
- 16. #AskShadow 7.715 posts
- 17. Nancy Mace 20,6 B posts
- 18. Mixon 18,3 B posts
- 19. Astrid 14 B posts
- 20. Cooper Rush 12 B posts
Something went wrong.
Something went wrong.